Host CD4+ cells are required for engraftment promotion by anti-CD154 monoclonal antibody
| mAb . | No. chimeric . | % Donor . |
|---|---|---|
| None | 0/10 | 0 |
| Anti-CD154 | 0/10 | 62 ± 66-150 |
| Anti-CD154 + depleting anti-CD4 | 0/10 | 06-151 |
| Nondepleting anti-CD4 | 0/10 | 06-151 |
| Anti-CD154 + nondepleting anti-CD4 | 9/10 | 49 ± 286-150 |
| mAb . | No. chimeric . | % Donor . |
|---|---|---|
| None | 0/10 | 0 |
| Anti-CD154 | 0/10 | 62 ± 66-150 |
| Anti-CD154 + depleting anti-CD4 | 0/10 | 06-151 |
| Nondepleting anti-CD4 | 0/10 | 06-151 |
| Anti-CD154 + nondepleting anti-CD4 | 9/10 | 49 ± 286-150 |
B6 mice were irradiated with 200 cGy TBI on day −1 and infused with 40 × 106 BALB/c BM on day 0. Anti-CD154 mAb was administered daily from day −1 through day 5 daily, then twice a week until day 14 at 200 μg/dose. Four hundred micrograms depleting anti-CD4 was given on days −2, 1, 5, and 9, and 1 mg nondepleting anti-CD4 was given on days −1, 1, 3, 5, 8, and 11. PBLs were typed for percentage donor-host chimerism at 6 weeks after BMT. Ten mice per group underwent transplantation. No. chimeric indicates number of mice with more than 3% donor cells. Shown is average percentage donor ± 1 SD of all mice in group.
For abbreviations, see Table 1.
P ≤ .002 compared with untreated controls.
P = .160, anti-CD154 administered alone versus in combination with nondepleting anti-CD4.